CALIWAY BIOPHARMACEUTICALS
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Caliway Announces FDA Clearance of IND Application for CBL-514 to Proceed with SUPREME-01, the First Global Pivotal Phase 3 Study for Reducing Abdominal Subcutaneous Fat 2025-07-28 17:51
Caliway to Present First Preclinical Data on CBL-514 for GLP-1 Weight Rebound Management at BIO 2025 2025-06-10 16:15
Caliway Announces Successful EOP2 Meeting with the FDA for CBL-514 in Reduction of Abdominal Subcutaneous Fat 2025-05-14 13:38
Caliway Announces Successful EOP2 Meeting with the FDA for CBL-514 in Reduction of Abdominal Subcutaneous Fat 2025-05-14 12:01
Caliway Selected to Present CBL-514 Phase 2 Study Results for Dercum's Disease at World Orphan Drug Congress USA 2025 2025-04-17 18:34
Caliway's CBL-514 Phase 2 Study (CBL-0202) Accepted for Publication in the Aesthetic Surgery Journal 2025-03-12 14:29
Caliway Announces CBL-514 Second Phase 2b Study Results (CBL-0205) Met Endpoints 2025-02-10 14:15
Caliway to Present CBL-514 Phase 2b Study Results for Subcutaneous Fat Reduction at IMCAS 2025 in Paris 2024-12-19 10:47
Caliway Biopharmaceuticals Included in FTSE TWSE Taiwan Eight Industries and Mid-Cap 100 Indices 2024-12-07 08:57
Caliway Announced EMA Orphan Drug Designation Granted to CBL-514 for Dercum's Disease Treatment 2024-11-13 13:36
Caliway Completed CBL-514 Phase 2b Study (CBL-0205) for Subcutaneous Fat Reduction 2024-10-24 01:42
Caliway Announces the Initiation of Subject Recruitment in CBL-514 Phase 2b Study for Dercum's Disease 2024-09-03 15:18
Caliway to Present the Latest Clinical Advancements at 2024 BIO International Convention 2024-05-11 15:14
Caliway Announced CBL-514 Phase 2 Study for Cellulite Treatment Met All Primary and Secondary Endpoints 2024-04-26 01:25
Caliway Announced Orphan Drug Designation Granted to CBL-514 for the Treatment of Dercum's Disease 2024-03-04 16:22
Caliway Announced Orphan Drug Designation Granted to CBL-514 for the Treatment of Dercum's Disease 2024-03-04 07:00
Caliway Received First Approval of CBL-514 Pivotal Phase 3 Study Application for Subcutaneous Fat Reduction 2024-01-23 21:12
Caliway Received First Approval of CBL-514 Pivotal Phase 3 Study Application for Subcutaneous Fat Reduction 2024-01-23 18:35
Caliway Announces FDA Acceptance of CBL-514 IND Application for Placebo-Controlled Phase 2 Study to treat Dercum's Disease 2024-01-08 13:25
Caliway to Present CBL-514 Phase 2 Study Results for Subcutaneous Fat Reduction at IMCAS 2024 2023-12-27 11:49
1 2